Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay

Takafumi Kuzuya, Yozo Ogura, Yoko Motegi, Natsuko Moriyama, Toshitaka Nabeshima

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 μg/L and 15 μg/L. Both coefficients of variation were over 20% (21% at 7.5 μg/L of tacrolimus and 22% at 15 μg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.54; P < 0.0001 at 15 μg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.91; P < 0.0001 at 15 μg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.

Original languageEnglish
Pages (from-to)507-511
Number of pages5
JournalTherapeutic Drug Monitoring
Volume24
Issue number4
DOIs
Publication statusPublished - 19-08-2002
Externally publishedYes

Fingerprint

Tacrolimus
Immunoenzyme Techniques
Hematocrit
Bilirubin
Alkaline Phosphatase
Sodium Chloride
Cyclosporine
Reference Values

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kuzuya, Takafumi ; Ogura, Yozo ; Motegi, Yoko ; Moriyama, Natsuko ; Nabeshima, Toshitaka. / Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. In: Therapeutic Drug Monitoring. 2002 ; Vol. 24, No. 4. pp. 507-511.
@article{f7c0651d050c45edbb4fd6d0fb28aee5,
title = "Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay",
abstract = "The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 μg/L and 15 μg/L. Both coefficients of variation were over 20{\%} (21{\%} at 7.5 μg/L of tacrolimus and 22{\%} at 15 μg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.54; P < 0.0001 at 15 μg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.91; P < 0.0001 at 15 μg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.",
author = "Takafumi Kuzuya and Yozo Ogura and Yoko Motegi and Natsuko Moriyama and Toshitaka Nabeshima",
year = "2002",
month = "8",
day = "19",
doi = "10.1097/00007691-200208000-00008",
language = "English",
volume = "24",
pages = "507--511",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. / Kuzuya, Takafumi; Ogura, Yozo; Motegi, Yoko; Moriyama, Natsuko; Nabeshima, Toshitaka.

In: Therapeutic Drug Monitoring, Vol. 24, No. 4, 19.08.2002, p. 507-511.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay

AU - Kuzuya, Takafumi

AU - Ogura, Yozo

AU - Motegi, Yoko

AU - Moriyama, Natsuko

AU - Nabeshima, Toshitaka

PY - 2002/8/19

Y1 - 2002/8/19

N2 - The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 μg/L and 15 μg/L. Both coefficients of variation were over 20% (21% at 7.5 μg/L of tacrolimus and 22% at 15 μg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.54; P < 0.0001 at 15 μg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.91; P < 0.0001 at 15 μg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.

AB - The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 μg/L and 15 μg/L. Both coefficients of variation were over 20% (21% at 7.5 μg/L of tacrolimus and 22% at 15 μg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.54; P < 0.0001 at 15 μg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93; P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.91; P < 0.0001 at 15 μg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.

UR - http://www.scopus.com/inward/record.url?scp=0036333913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036333913&partnerID=8YFLogxK

U2 - 10.1097/00007691-200208000-00008

DO - 10.1097/00007691-200208000-00008

M3 - Article

VL - 24

SP - 507

EP - 511

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 4

ER -